HGEN - Why Humanigen Stock Vaulted Higher Today
Shares of Humanigen (NASDAQ: HGEN) were vaulting 10.8% higher as of 2:47 p.m. EDT on Wednesday. The gain came after the company announced the publishing of results on the online preprint site medRxiv from a phase 3 study evaluating lenzilumab in treating hospitalized COVID-19 patients.
The late-stage study found that lenzilumab significantly improved survival without ventilation for hospitalized patients with COVID-19 compared to standard treatments of Gilead Sciences' remdesivir and/or corticosteroids by themselves. Patients with especially high inflammation levels and those under the age of 85 experienced the greatest benefit from receiving Humanigen's experimental therapy.
Image source: Getty Images.
For further details see:
Why Humanigen Stock Vaulted Higher Today